## Sami Viskin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3651932/publications.pdf

Version: 2024-02-01

158	10,350	31902	32761 100
papers	citations	h-index	g-index
163	163	163	6374
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Long QT syndromes and torsade de pointes. Lancet, The, 1999, 354, 1625-1633.	6.3	640
2	J-Point Elevation in Survivors of Primary Ventricular Fibrillation and Matched Control Subjects. Journal of the American College of Cardiology, 2008, 52, 1231-1238.	1.2	528
3	Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome. Circulation, 2004, 110, 1731-1737.	1.6	443
4	Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Journal of the American College of Cardiology, 2011, 57, 2244-2254.	1.2	352
5	Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. Heart Rhythm, 2005, 2, 569-574.	0.3	345
6	The pathophysiological mechanism underlying Brugada syndrome. Journal of Molecular and Cellular Cardiology, 2010, 49, 543-553.	0.9	323
7	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm, 2016, 13, e295-e324.	0.3	322
8	Mandatory Electrocardiographic Screening of Athletes to Reduce Their Risk for Sudden Death. Journal of the American College of Cardiology, 2011, 57, 1291-1296.	1.2	277
9	Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age). Circulation, 2014, 130, 1303-1334.	1.6	234
10	Idiopathic ventricular fibrillation. American Heart Journal, 1990, 120, 661-671.	1.2	224
11	Torsade de Pointes Due to Noncardiac Drugs. Medicine (United States), 2003, 82, 282-290.	0.4	214
12	Mutations in SCN10A Are Responsible for a Large Fraction of Cases of Brugada Syndrome. Journal of the American College of Cardiology, 2014, 64, 66-79.	1.2	212
13	The Morphology of the QT Interval Predicts Torsade de Pointes During Acquired Bradyarrhythmias. Journal of the American College of Cardiology, 2007, 49, 320-328.	1.2	206
14	Effects of Electrophysiologic-Guided Therapy with Class IA Antiarrhythmic Drugs on the Long-Term Outcome of Patients with Idiopathic Ventricular Fibrillation with or without the Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 1999, 10, 1301-1312.	0.8	202
15	The Response of the QT Interval to the Brief Tachycardia Provoked by Standing. Journal of the American College of Cardiology, 2010, 55, 1955-1961.	1.2	198
16	Distinguishing "benign―from "malignant early repolarization― The value of the ST-segment morphology. Heart Rhythm, 2012, 9, 225-229.	0.3	198
17	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.3	197
18	Derivation and Validation of a Simple Exercise-Based Algorithm for Prediction of Genetic Testing in Relatives of LQTS Probands. Circulation, 2011, 124, 2187-2194.	1.6	182

#	Article	IF	CITATIONS
19	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. European Journal of Preventive Cardiology, 2017, 24, 41-69.	0.8	181
20	Assessment of the 12-Lead Electrocardiogram asÂaÂScreening Test for Detection of Cardiovascular DiseaseÂinÂHealthy General Populations of Young PeopleÂ(12–25ÂYears of Age). Journal of the American College of Cardiology, 2014, 64, 1479-1514.	1.2	180
21	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Europace, 2017, 19, euw235.	0.7	172
22	Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2007, 4, 1149-1154.	0.3	163
23	The "Short-Coupled―Variant of Right Ventricular Outflow Ventricular Tachycardia: A Not-So-Benign Form of Benign Ventricular Tachycardia?. Journal of Cardiovascular Electrophysiology, 2005, 16, 912-916.	0.8	162
24	Idiopathic Ventricular Tachycardia and Fibrillation. Journal of Cardiovascular Electrophysiology, 1993, 4, 356-368.	0.8	156
25	Mode of onset of torsade de pointes in congenital long QT syndrome. Journal of the American College of Cardiology, 1996, 28, 1262-1268.	1.2	147
26	Fever-induced Brugada pattern: How common is it and what does it mean?. Heart Rhythm, 2013, 10, 1375-1382.	0.3	145
27	The QT interval: Too long, too short or just right. Heart Rhythm, 2009, 6, 711-715.	0.3	134
28	Mode of Onset of Malignant Ventricular Arrhythmias in Idiopathic Ventricular Fibrillation. Journal of Cardiovascular Electrophysiology, 1997, 8, 1115-1120.	0.8	133
29	Jâ€Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Journal of Arrhythmia, 2016, 32, 315-339.	0.5	125
30	Risk of sudden death among young individuals with J waves and early repolarization: Putting the evidence into perspective. Heart Rhythm, 2011, 8, 923-929.	0.3	120
31	Is idiopathic ventricular fibrillation a short QT syndrome? Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. Heart Rhythm, 2004, 1, 587-591.	0.3	118
32	Empiric quinidine therapy for asymptomatic Brugada syndrome: Time for a prospective registry. Heart Rhythm, 2009, 6, 401-404.	0.3	106
33	Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: Classification, differential diagnosis, and implications for therapy. Progress in Cardiovascular Diseases, 1998, 41, 17-34.	1.6	105
34	Cardiac Pacing in the Long QT Syndrome: Journal of Cardiovascular Electrophysiology, 2000, $11$ , 593-599.	0.8	105
35	Excellent Longâ€Term Reproducibility of the Electrophysiologic Efficacy of Quinidine in Patients with Idiopathic Ventricular Fibrillation and Brugada Syndrome. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 294-301.	0.5	104
36	Management of patients with palpitations: a position paper from the European Heart Rhythm Association. Europace, 2011, 13, 920-934.	0.7	99

#	Article	IF	CITATIONS
37	Risk stratification in Brugada syndrome: Clinical characteristics, electrocardiographic parameters, and auxiliary testing. Heart Rhythm, 2016, 13, 299-310.	0.3	98
38	Management of Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1393-1402.	2.1	97
39	Life-Threatening Events During Endurance Sports. Journal of the American College of Cardiology, 2014, 64, 463-469.	1.2	87
40	Quinidine, A Life-Saving Medication for BrugadaÂSyndrome,Âls Inaccessible in Many Countries. Journal of the American College of Cardiology, 2013, 61, 2383-2387.	1.2	86
41	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	0.7	86
42	Pause-dependent torsade de pointes following acute myocardial infarction. Journal of the American College of Cardiology, 2001, 38, 1168-1174.	1.2	82
43	The phenomenon of "QT stunning― The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm, 2012, 9, 901-908.	0.3	77
44	Preventing Sudden Death of Athletes With Electrocardiographic Screening. Journal of the American College of Cardiology, 2012, 60, 2271-2276.	1.2	75
45	Long QT syndrome caused by noncardiac drugs. Progress in Cardiovascular Diseases, 2003, 45, 415-427.	1.6	69
46	Determinants of Effort Intolerance in Patients With Heart Failure. JACC: Heart Failure, 2015, 3, 803-814.	1.9	69
47	Prognostic significance of fever-induced Brugada syndrome. Heart Rhythm, 2016, 13, 1515-1520.	0.3	68
48	Quinidine: a valuable medication joins the list of 'endangered species'. Europace, 2007, 9, 1105-1106.	0.7	65
49	Antagonist: Routine screening of all athletes prior to participation in competitive sports should be mandatory to prevent sudden cardiac death. Heart Rhythm, 2007, 4, 525-528.	0.3	62
50	Aminophylline for Bradyasystolic Cardiac Arrest Refractory to Atropine and Epinephrine. Annals of Internal Medicine, 1993, 118, 279.	2.0	60
51	What Do We Know About the "MalignantÂFormâ€Âof Early Repolarization?. Journal of the American College of Cardiology, 2013, 62, 863-868.	1.2	59
52	Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. Heart Rhythm, 2007, 4, 1072-1080.	0.3	58
53	Ranolazine for Congenital Long-QT Syndrome Type III. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	56
54	Asymptomatic Brugada syndrome: a cardiac ticking time-bomb?. Europace, 2007, 9, 707-710.	0.7	53

#	Article	IF	CITATIONS
55	Everybody has Brugada syndrome until proven otherwise?. Heart Rhythm, 2015, 12, 1595-1598.	0.3	47
56	A Tale of 2 Diseases. Journal of the American College of Cardiology, 2016, 67, 100-108.	1.2	47
57	Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. European Heart Journal, 2006, 27, 469-475.	1.0	46
58	Atrial Fibrillation, Stroke, and Mortality Rates After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 114, 1861-1866.	0.7	45
59	Continuous heart rate monitoring for automatic detection of atrial fibrillation with novel bio-sensing technology. Journal of Electrocardiology, 2019, 52, 23-27.	0.4	44
60	Drug-induced Brugada syndrome: Clinical characteristics and risk factors. Heart Rhythm, 2016, 13, 1083-1087.	0.3	42
61	Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. Circulation, 2019, 139, 2304-2314.	1.6	42
62	Making sense of early repolarization. Heart Rhythm, 2012, 9, 566-569.	0.3	41
63	Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart Rhythm, 2020, 17, 1452-1455.	0.3	40
64	Idiopathic Ventricular Fibrillation "Le Syndrome d'HaÃ⁻ssaguerre―and the Fear of J Waves. Journal of the American College of Cardiology, 2009, 53, 620-622.	1.2	38
65	Diagnostic value of T-wave morphology changes during "QT stretching―in patients with long QT syndrome. Heart Rhythm, 2015, 12, 2263-2271.	0.3	38
66	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverterâ€defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	0.5	34
67	Radiofrequency ablation of paroxysmal atrial fibrillation with the new irrigated multipolar nMARQ ablation catheter: Verification of intracardiac signals with a second circular mapping catheter. Heart Rhythm, 2014, 11, 559-565.	0.3	33
68	Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort. European Journal of Preventive Cardiology, 2019, 26, 764-775.	0.8	32
69	Female gender as independent risk factor of torsades de pointes during acquired atrioventricular block. Heart Rhythm, 2017, 14, 90-95.	0.3	31
70	Polymorphic ventricular tachycardia, ischaemic ventricular fibrillation, and torsade de pointes: importance of the QT and the coupling interval in the differential diagnosis. European Heart Journal, 2021, 42, 3965-3975.	1.0	28
71	When You Only Live Twice. New England Journal of Medicine, 1995, 332, 1221-1225.	13.9	26
72	Long QT Syndrome Complicating Atrioventricular Block. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1129-1135.	2.1	26

#	Article	IF	CITATIONS
73	New formula for defining "normal―and "prolonged―QT in patients with bundle branch block. Journal of Electrocardiology, 2018, 51, 481-486.	0.4	23
74	Polymorphic Ventricular Tachycardia: Terminology, Mechanism, Diagnosis, and Emergency Therapy. Circulation, 2021, 144, 823-839.	1.6	23
75	Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm, 2011, 8, 1546-1552.	0.3	22
76	Prevention of ventricular arrhythmias in the congenital long QT syndrome. Current Cardiology Reports, 2000, 2, 492-497.	1.3	21
77	Long-term flecainide therapy in type 3 long QT syndrome. Europace, 2018, 20, 370-376.	0.7	20
78	Simplified "ATP Test" for Noninvasive Diagnosis of Dual AV Nodal Physiology and Assessment of Results of Slow Pathway Ablation in Patients with AV Nodal Reentrant Tachycardia. Journal of Cardiovascular Electrophysiology, 2000, 11, 255-261.	0.8	19
79	J waves and early repolarization: Do not confuse me with the facts!. Heart Rhythm, 2012, 9, 1603-1604.	0.3	19
80	Grapefruit juice prolongs the QT interval of healthy volunteers and patients with long QT syndrome. Heart Rhythm, 2019, 16, 1141-1148.	0.3	18
81	Noninvasive and Invasive Strategies for the Prevention of Sudden Death after Myocardial Infarction. Drugs, 1992, 44, 336-355.	4.9	16
82	What Is the Drug of Choice for the Acute Termination of Paroxysmal Supraventricular Tachycardia: Verapamil, Adenosine Triphosphate, or Adenosine?. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 1735-1741.	0.5	16
83	Torsades de pointes. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 187-195.	0.4	16
84	Electrocardiographic Manifestations of Calcium Abnormalities. , 2016, 21, 7-9.		16
85	Effect of pacemaker implantation after transcatheter aortic valve replacement on long- and mid-term mortality. Heart Rhythm, 2021, 18, 199-206.	0.3	16
86	Radiofrequency Ablation of Atrial Fibrillation: Nonrandomized Comparison of Circular versus Pointâ€byâ€Point "Smart―Ablation for Achieving Circumferential Pulmonary Vein Isolation and Curing Arrhythmic Symptoms. Journal of Cardiovascular Electrophysiology, 2016, 27, 1282-1287.	0.8	15
87	Quinidine-responsive out-of-hospital polymorphic ventricular tachycardia in patients with coronary heart disease. Europace, 2020, 22, 265-273.	0.7	15
88	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	1.0	15
89	Treatable causes of sudden death: not really "treatable―or not really the cause?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. Journal of the American College of Cardiology. 2001. 38, 1725-1727.	1.2	12
90	Brugada burden in Brugada syndrome: The way to go in risk stratification?. Heart Rhythm, 2013, 10, 1019-1020.	0.3	12

#	Article	IF	CITATIONS
91	Inaccessibility to Quinidine Therapy Is About to Get Worse. Journal of the American College of Cardiology, 2013, 62, 355.	1.2	12
92	Radiofrequency Ablation of Asymptomatic Brugada Syndrome. Circulation, 2018, 137, 1883-1884.	1.6	12
93	Attempts to prevent "tongue swallowing―may well be the main obstacle for successful bystander resuscitation of athletes with cardiac arrest. Heart Rhythm, 2017, 14, 1729-1734.	0.3	11
94	Amyloid goiter: Report of the clinical, histological and biochemical features of five cases. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 119-125.	1.4	10
95	Near Fatal Ventricular Fibrillation in Brugada Syndrome Despite Presence of an Implanted Implantable CardioverterÂDefibrillator. Canadian Journal of Cardiology, 2014, 30, 1460.e3-1460.e5.	0.8	10
96	Pro-Arrhythmic Effects of Noncardiac Medications. Journal of the American College of Cardiology, 2015, 66, 2185-2188.	1.2	10
97	Continuous heart rhythm monitoring using mobile photoplethysmography in ambulatory patients. Journal of Electrocardiology, 2020, 60, 138-141.	0.4	10
98	Continuous Heart Rate Monitoring for Automatic Detection of Life-Threatening Arrhythmias With Novel Bio-Sensing Technology. Frontiers in Cardiovascular Medicine, 2021, 8, 707621.	1.1	10
99	Read My Lips. JACC: Clinical Electrophysiology, 2017, 3, 1409-1411.	1.3	9
100	ldiopathic Polymorphic Ventricular Tachycardia: a "Benign Disease―with a Touch of Bad Luck?. Korean Circulation Journal, 2017, 47, 299.	0.7	9
101	Postâ€Tachycardia QT Prolongation:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 659-661.	0.5	8
102	Shooting at ambulances in Israel: a cardiologist's viewpoint. Lancet, The, 2003, 361, 1470-1471.	6.3	8
103	Reply. Journal of the American College of Cardiology, 2014, 63, 1812-1813.	1.2	8
104	Role of intracardiac echocardiography for guiding ablation of tricuspid valve arrhythmias. HeartRhythm Case Reports, 2018, 4, 209-213.	0.2	8
105	Ventricular fibrillation after ablation of a benign arrhythmia. Angry Purkinje syndrome?. HeartRhythm Case Reports, 2020, 6, 937-941.	0.2	8
106	Ventricular Flutter Induced During Electrophysiologic Studies in Patients with Old Myocardial Infarction:. Clinical and Electrophysiologic Predictors, and Prognostic Significance. Journal of Cardiovascular Electrophysiology, 2003, 14, 913-919.	0.8	7
107	The acquired Brugada syndrome and the paradox of choice. Heart Rhythm, 2009, 6, 1342-1344.	0.3	7
108	To the Editor—Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm, 2010, 7, 863.	0.3	7

#	Article	IF	Citations
109	Should Electrophysiological Studies Be Performed in Asymptomatic Patients Following Myocardial Infarction? A Pragmatic Approach. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 1082-1089.	0.5	6
110	Malignant early repolarization: It's the T-wave, stupid…. Heart Rhythm, 2016, 13, 903-904.	0.3	6
111	Type†Paradox of Brugada Syndrome. Journal of the American Heart Association, 2018, 7, .	1.6	6
112	Important Developments in Long QT Syndrome. Circulation, 2020, 142, 2416-2419.	1.6	6
113	Clinical Presentation of Sustained Monomorphic Ventricular Tachycardia Without Cardiac Arrest. Journal of the American Heart Association, 2020, 9, e016673.	1.6	6
114	Prediction of Sudden Death after Myocardial Infarction: Value of Electrophysiologic Parameters. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 193-197.	0.9	5
115	Prediction versus prevention of sudden cardiac death. Lancet, The, 2006, 367, 1639-1641.	6.3	5
116	Management of Idiopathic Ventricular Fibrillation: Implantable Defibrillators? Antiarrhythmic Drugs?. Annals of Noninvasive Electrocardiology, 1998, 3, 125-128.	0.5	5
117	Is There Anyone Left With a Normal Electrocardiogram?. Journal of the American College of Cardiology, 2013, 62, 1619-1620.	1.2	5
118	Clinical Features of Genetic Cardiac Diseases Related to Potassium Channelopathies. Cardiac Electrophysiology Clinics, 2016, 8, 361-372.	0.7	5
119	Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726.	2.1	5
120	Long QT Syndrome and Torsade de Pointes Ultimately Treated With Quinidine: Introducing the Concept of Pseudo–Torsade de Pointes. Circulation, 2021, 144, 85-89.	1.6	5
121	Reconstruction of the left atrium for atrial fibrillation ablation using the machine learning CARTO 3Âm-FAM software. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 39-47.	0.6	5
122	Short-coupled premature ventricular beats leading to ventricular fibrillation in a young patient: A Sudden Arrhythmia Death Syndrome case report and literature review. HeartRhythm Case Reports, 2020, 6, 815-818.	0.2	5
123	Explaining Sudden Unexplained Death. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 879-881.	2.1	4
124	Theophylline: The forgotten antiarrhythmic drug… now for malignant early repolarization. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 441-443.	0.5	4
125	Editorial commentary: A question on proarrhythmic food: Is grapefruit "the forbidden fruit―for patients with long QT syndrome?. Trends in Cardiovascular Medicine, 2020, 30, 313-314.	2.3	4
126	Ranolazine: Déjà vu of the amiodarone story. Heart Rhythm, 2011, 8, 1291-1292.	0.3	3

#	Article	IF	CITATIONS
127	Exercise-induced Ventricular Tachycardia/Ventricular Fibrillation in the Normal Heart. Cardiac Electrophysiology Clinics, 2016, 8, 593-600.	0.7	3
128	J-Wave Syndromes. , 2018, , 917-924.		3
129	Will I Die From Brugada Syndrome?. JACC: Clinical Electrophysiology, 2021, 7, 223-225.	1.3	3
130	The top 10 reasons to avoid electrophysiology studies in Brugada syndrome. Heart Rhythm, 2021, 18, 672-673.	0.3	3
131	Bedwetting from the heart: Time for a paradigm shift in the minimal diagnostic evaluation of enuresis. Heart Rhythm, 2022, 19, 862-865.	0.3	3
132	Atrial Tachycardia and "Kissing Catheters". Journal of Cardiovascular Electrophysiology, 2000, 11, 233-233.	0.8	2
133	QT Interval and Mortality. Archives of Internal Medicine, 2011, 171, 1734.	4.3	2
134	Early repolarization and arrhythmic death: Six more years?. Trends in Cardiovascular Medicine, 2015, 25, 31-32.	2.3	2
135	Syncope in Hereditary Arrhythmogenic Syndromes. Cardiology Clinics, 2015, 33, 433-440.	0.9	2
136	Using registries to predict outcome: the implantable cardioverter-defibrillator in long QT syndrome. Europace, 2019, 21, 188-189.	0.7	2
137	Clinically Significant High-Grade AV Block as a Reversible Cause for Acute Kidney Injury in Hospitalized Patientsâ€"A Propensity Score Matched Cohort. Journal of Clinical Medicine, 2021, 10, 2424.	1.0	2
138	Arrhythmic storm from ischemic ventricular fibrillation treated with intravenous quinidine. Journal of Electrocardiology, 2021, 68, 141-144.	0.4	2
139	Prevention of Cardiac Arrest: Risk Assessment after Myocardial Infarction. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 180-183.	0.9	1
140	Call "the Cleaners― JACC: Clinical Electrophysiology, 2015, 1, 323-325.	1.3	1
141	Reply. Journal of the American College of Cardiology, 2015, 65, 408-409.	1.2	1
142	Should we do †whatever it takes†or †whatever is best†to prevent cardiac arrest in high-risk patients?. European Heart Journal, 2019, 40, 2962-2963.	1.0	1
143	Pulmonary Vein Isolation With Ablation Index via Single Transseptal Crossing: Critical Role of Carina Isolation. Heart Lung and Circulation, 2021, 30, 1373-1378.	0.2	1
144	Benign Versus Malignant Early Repolarization Patterns. , 2020, , 277-283.		1

#	Article	IF	CITATIONS
145	Intravenous chlorpromazine for the emergency treatment of uncontrolled symptomatic hypertension in the pre-hospital setting: data from 500 consecutive cases. Israel Medical Association Journal, 2005, 7, 812-5.	0.1	1
146	Sinus Node Dysfunction With a Nice Twist. Circulation, 2022, 145, 1285-1287.	1.6	1
147	Reply. Journal of the American College of Cardiology, 2013, 61, 1554.	1.2	0
148	J Wave Syndromes. , 2014, , 959-965.		0
149	From Whole Exome Sequencing to Patientâ€Specific Therapy: Another Example of How Basic Research Pays Off in Patient Care. Journal of the American Heart Association, 2015, 4, .	1.6	0
150	Reply. Journal of the American College of Cardiology, 2016, 67, 2806-2807.	1.2	0
151	Reply to the Editorâ€"Minimal QT, not just maximal, may underlie Tdp risk in women. Heart Rhythm, 2017, 14, e51.	0.3	0
152	Should theophylline be added to the J wave syndrome therapeutic armamentarium?. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 439-440.	0.5	0
153	Response by Viskin to Letter Regarding Article, "Radiofrequency Ablation of Asymptomatic Brugada Syndrome: Don't Go Burning My Heartâ€, Circulation, 2018, 138, 2584-2585.	1.6	0
154	Incessant atrial and ventricular tachycardias associated with an SCN5A mutation. HeartRhythm Case Reports, 2021, 7, 806-811.	0.2	0
155	Increased Vagal Activity in Idiopathic VF. Circulation, 1998, 97, .	1.6	0
156	Risk Stratification in Brugada Syndrome: Clinical Characteristics, Electrocardiographic Parameters and Auxiliary Testing., 2016, , 173-191.		0
157	Please take a moment to study this electrocardiogram: it may help you prevent a sudden death. Israel Medical Association Journal, 2002, 4, 393-4.	0.1	0
158	Abstract 21344: Mutations in <i>CACNA1C</i> and <i>KCNE2</i> Genes are Associated With Brugada Syndrome and Epilepsy. Circulation, 2017, 136, .	1.6	0